Samuel Yoon
Overview
Explore the profile of Samuel Yoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knox A, Cominsky L, Sun D, Cruz Cabrera E, Nolan B, Ofray E, et al.
Blood
. 2025 Jan;
PMID: 39854693
Leukopoiesis is lethally arrested in mice lacking the master transcriptional regulator PU.1. Depending on the animal model, subtotal PU.1 loss either induces acute myeloid leukemia or arrests early B cell...
2.
Haddadin R, Aboujamra D, Kapadia K, Yoon S, Zahlan Z, Buczek L, et al.
J Community Hosp Intern Med Perspect
. 2025 Jan;
14(6):104-107.
PMID: 39839164
Paraneoplastic limbic encephalitis (PLE) is a poorly understood condition, thought to be caused by the cross-reacting of tumor antibodies with neurons in the brain, resulting in neuropsychiatric sequelae, such as...
3.
Al-Zakri M, Eren A, Cahill P, Jaakkimainen L, To T, Bouchard M, et al.
Can J Surg
. 2024 Nov;
67(6suppl1):S17-S76.
PMID: 39537311
No abstract available.
4.
Le Coz C, Trofa M, Butler D, Yoon S, Tian T, Reid W, et al.
J Allergy Clin Immunol
. 2024 May;
154(3):778-791.e9.
PMID: 38692308
Background: Autoimmune cytopenias (AICs) regularly occur in profoundly IgG-deficient patients with common variable immunodeficiency (CVID). The isotypes, antigenic targets, and origin(s) of their disease-causing autoantibodies are unclear. Objective: We sought...
5.
Wallach J, Yoon S, Doernberg H, Glick L, Ciani O, Taylor R, et al.
JAMA
. 2024 Apr;
331(19):1646-1654.
PMID: 38648042
Importance: Surrogate markers are increasingly used as primary end points in clinical trials supporting drug approvals. Objective: To systematically summarize the evidence from meta-analyses, systematic reviews and meta-analyses, and pooled...
6.
Sakhrekar R, Iorio C, Yoon S, Monjardino M, Lewis S, Gray R
J Orthop Case Rep
. 2024 Apr;
14(3):168-175.
PMID: 38560320
Introduction: Ewing sarcoma (ES) is a malignant and aggressive bony tumor affecting the most common age group of 5-20 years. It constitutes 10%-15% of all bone sarcomas and is the...
7.
Law V, Cohen D, Chan B, Singh S, Jones C, Papachristos A, et al.
BMJ Open Qual
. 2023 Dec;
12(4).
PMID: 38148117
Background: Opioid overprescribing is commonplace after total hip (THA) and total knee arthroplasty (TKA). Preliminary data demonstrated that approximately 32% of the opioids prescribed at discharge from our hospital following...
8.
Le Coz C, Oldridge D, Herati R, De Luna N, Garifallou J, Cruz Cabrera E, et al.
Sci Immunol
. 2023 Apr;
8(82):eade8162.
PMID: 37027481
The mechanisms by which FOXP3 T follicular regulatory (Tfr) cells simultaneously steer antibody formation toward microbe or vaccine recognition and away from self-reactivity remain incompletely understood. To explore underappreciated heterogeneity...
9.
Tat J, Tat J, Yoon S, Yee A, Larouche J
Spine (Phila Pa 1976)
. 2021 Sep;
47(2):E73-E85.
PMID: 34474449
Study Design: Systematic review. Objective: The aim of this study was to review the current spine surgery literature to establish a definition for adequate spine decompression using intraoperative ultrasound (IOUS)...
10.
Le Coz C, Nguyen D, Su C, Nolan B, Albrecht A, Xhani S, et al.
J Exp Med
. 2021 May;
218(7).
PMID: 33951726
The pioneer transcription factor (TF) PU.1 controls hematopoietic cell fate by decompacting stem cell heterochromatin and allowing nonpioneer TFs to enter otherwise inaccessible genomic sites. PU.1 deficiency fatally arrests lymphopoiesis...